12.10.2020 |
EN |
Official Journal of the European Union |
C 339/32 |
Action brought on 27 August 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXIMBLIS)
(Case T-542/20)
(2020/C 339/40)
Language in which the application was lodged: German
Parties
Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: Pfizer Inc. (New York, New York, United States)
Details of the proceedings before EUIPO
Applicant for the trade mark at issue: Applicant
Trade mark at issue: Application for EU word mark RUXIMBLIS — Application No. 17 865 738
Procedure before EUIPO: Opposition proceedings
Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 16 June 2020 in Case R 1877/2019-4
Form of order sought
The applicant claims that the Court should:
— |
annul the contested decision; |
— |
order EUIPO to pay the costs, including the costs of the proceedings before the Board of Appeal. |
Plea in law
Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.